Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Monoclonal antibodies (mAbs) are a well established class of therapeutics as evidenced by a large number of FDA approved mAbs for the treatment of cancers and autoimmune diseases. Monoclonal antibodies that are molecularly engineered for enhanced functions and pharmacokinetic properties are routinely being considered for development by many biotechnology companies. Safety evaluation of current generation of mAbs poses new challenges due to the highly complex nature of engineering aspects and variability induced by the diverse recombinant cell systems to generate them. This review provides a basic outline for nonclinical safety evaluation of therapeutic antibodies. Important considerations for planning a preclinical program, the types of nonclinical safety studies, and a general timeline for their conduct in relation to clinical trials are described. A list of relevant regulatory documents issued by government agencies is also provided. Adoption of these principles will greatly enhance the quality and relevance of the nonclinical safety data generated and will facilitate future development of mAb therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Human antibodies from transgenic animals.
Lonberg, N. (2005) · Nature Biotechnology · doi:10.1038/nbt1135 · Cited by 434
Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients
Sidiropoulos, P. I., & Boumpas, D. T. (2004) · Lupus · doi:10.1191/0961203304lu1032oa · Cited by 178
van Gerven, J., & Bonelli, M. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13550 · Cited by 162
Preclinical safety testing of monoclonal antibodies: the significance of species relevance
Chapman, K., Pullen, N., Graham, M., & Ragan, I. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2242 · Cited by 121
Cited by
Neutrophil Elastase, Proteinase 3, and Cathepsin G as Therapeutic Targets in Human Diseases
Korkmaz, B., Horwitz, M. S., Jenne, D. E., & Gauthier, F. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.002733 · Cited by 870
Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies
Brennan, F. R., Morton, L. D., Spindeldreher, S., Kiessling, A., Allenspach, R., Hey, A., Müller, P., Frings, W., & Sims, J. (2010) · mAbs · doi:10.4161/mabs.2.3.11782 · Cited by 250
“Such studies should be designed to define safe dosing regimens for clinical trials, including recommending a safe starting dose for FIH studies, identify target organs for toxicity and reversibility of any toxic effect, characterize the pharmacological response and how it relates to any observed toxicity, identify imm…”
BackgroundTamaki, C., Nagayama, T., Hashiba, M., Fujiyoshi, M., Hizue, M., Kodaira, H., Nishida, M., Suzuki, K., Takashima, Y., Ogino, Y., et al. (2013) · The Journal of Toxicological Sciences · doi:10.2131/jts.38.581 · Cited by 79
Preclinical Development of Nononcogenic Drugs (Small and Large Molecules)
Colerangle, J. B. (2017) · A Comprehensive Guide to Toxicology in Nonclinical Drug Development · doi:10.1016/b978-0-12-803620-4.00025-6 · Cited by 37
Metadata
- Authors
- Lynch, C. M., Hart, B. W., & Grewal, I. S.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2009-01
- Volume
- 1
- Issue
- 1
- Pages
- 2-11
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2034886862
- Cited by
- 59
- References
- 6
- FWCI
- 3.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.